TNRC6A

Across TCGA pan-cancer cohorts, TNRC6A Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated TNRC6A data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher TNRC6A Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated TNRC6A expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

STAD, LUSC, and SCLC are the cancer types where TNRC6A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	II,III,IV	1.000	0.593	.014	21	view →
LUSC	DFS	Median	III,IV	0.079	0.658	<.001	18	view →
SCLC	OS	Median	All	0.164	0.661	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	0.892	0.611	.017	6	view →
COAD	DFS	Median	III,IV	0.202	0.531	.028	5	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
SKCM	DFS	Median	III,IV	0.139	0.654	.013	3	view →
BLCA	DFS	Median	IV	0.385	0.479	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

TNRC6A–STAD (DFS)

Open the STAD breakdown →